GSK, the company formerly known as Glaxosmithkline, said on Monday its blood cancer drug Blenrep, when used as a second-line treatment in patients with myeloma, met its primary goal of progression ...

It's the second blow to GSK's cancer drugs portfolio in the space of a week, after the company revealed that its BCMA-targeting drug Blenrep (belantamab mafodotin) failed to meet its objectives in ...

Enter: “Your Cancer Is Our Challenge,” a new initiative that GSK ... adding that they round out GSK’s drug-based efforts to ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GlaxoSmithKline is in a spree of producing new diabetes and cancer drugs which it hopes will increase its sales this year. After the recent U.S. drug approvals it is starting to market two of its ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

GSK will pay $300 million to acquire a bispecific antibody from Shanghai-based Chimagen Biosciences that it believes has the ...

Also, it is focusing more on oncology and the immune system, with genetic data to help develop the next generation of drugs. The benefits of these strategies are showing up in GSK's early-stage drugs.

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.